Immunotherapy advances

Keyphrases

Publications

volume 3, number 1, 2023

Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Lars Klareskog, Lars Alfredsson
Prevention vs treatment of rheumatoid arthritis. Immunotherapy advances 3 (1) (2023)
Akshay Jatin Patel, Gary W Middleton
TIGIT-based immunotherapeutics in lung cancer. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
Time to treat the climate and nature crisis as one indivisible global health emergency. Immunotherapy advances 3 (1) (2023)
Natalie Mona Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen M Ross, Frank Heuts, Yassin Elfaki, Luke P Houghton, Toby Talbot, Amna Sheri, Alexandra Pender, David Chao, Lucy Sarah Kate Walker
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy advances 3 (1) (2023)
Melissa M Christodoulidou, Neil A Mabbott
Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy advances 3 (1) (2023)
Megan Sykes
Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Michael J Walsh, Lestat R Ali, Patrick Lenehan, Courtney T Kureshi, Rakeeb Kureshi, Michael Dougan, David M Knipe, Stephanie K Dougan
Blockade of innate inflammatory cytokines TNF α , IL-1 β , or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Meiyin Lin, Sebastian Chakrit Bhakdi, Damien Tan, Joycelyn Jie Xin Lee, David Wai Meng Tai, Andrea Pavesi, Lu-En Wai, Tina Wang, Antonio Bertoletti, Anthony Tanoto Tan
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. Immunotherapy advances 3 (1) (2023)
Patrícia Silva Santos Ribeiro, Hanneke L D M Willemen, Sabine Versteeg, Christian Martin Gil, Niels Eijkelkamp
NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain. Immunotherapy advances 3 (1) (2023)
María José Mansilla, Catharien M U Hilkens, Eva M Martínez-Cáceres
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy advances 3 (1) (2023)
Katie R Flaherty, Stephanie Kucykowicz, Johannes Schroth, Will Traves, Kyle T Mincham, George E Finney
Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key? Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Natalie Mona Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen M Ross, Frank Heuts, Yassin Elfaki, Luke P Houghton, Toby Talbot, Amna Sheri, Alexandra Pender, David Chao, Lucy Sarah Kate Walker
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy advances 3 (1) (2023)
Ester Gea-Mallorqui, Sarah Rowland-Jones
DC-targeting lentivectors for cancer immunotherapy. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Sandra Kleinau
Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma. Immunotherapy advances 3 (1) (2023)
Winston M Zhu, Mark R Middleton
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunotherapy advances 3 (1) (2023)
Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw, null null
Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunotherapy advances 3 (1) (2023)
Shimon Sakaguchi, Ryoji Kawakami, Norihisa Mikami
Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)
Walter Bodmer
A historical perspective on HLA. Immunotherapy advances 3 (1) (2023)
Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances 3 (1) (2023)
Andrew Abaasa, Moses Egesa, Emmanuella Driciru, Jan Pieter R Koopman, Ronald Kiyemba, Richard E Sanya, Jacent Nassuuna, Agnes Ssali, Geofrey Kimbugwe, Anne Wajja, Govert J van Dam, Paul L A M Corstjens, Stephen Cose, Janet Seeley, Dorcas Kamuya, Emily L Webb, Maria Yazdanbakhsh, Pontiano Kaleebu, Afzal A Siddiqui, Narcis Kabatereine, Edridah Tukahebwa, Meta Roestenberg, Alison M Elliott
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Lúcia Silla
Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances 3 (1) (2023)

volume 3, number 1, 2022

A K Daramola, O A Akinrinmade, E A Fajemisin, Krupa Naran, N Mthembu, S Hadebe, F Brombacher, A M Huysamen, O E Fadeyi, R Hunter, S Barth
A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG + hybridomas in comparison to its recombinant allergen-drug conjugate. Immunotherapy advances 3 (1) (2022)
A K Daramola, O A Akinrinmade, E A Fajemisin, Krupa Naran, N Mthembu, S Hadebe, F Brombacher, A M Huysamen, O E Fadeyi, R Hunter, S Barth
A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG + hybridomas in comparison to its recombinant allergen-drug conjugate. Immunotherapy advances 3 (1) (2022)

volume 2, number 1, 2022

Rafaela Rossetti, Heloísa Brand, Sarah Caroline Gomes Lima, Izadora Peter Furtado, Roberta Maraninchi Silveira, Daianne Maciely Carvalho Fantacini, Dimas Tadeu Covas, Lucas Eduardo Botelho de Souza
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy advances 2 (1) (2022)
Tim Elliott
Immunotherapy advances: One year on. Immunotherapy advances 2 (1) (2022)
A Ammon, L Mellenthin, C Emmerich, E Naschberger, M Stürzl, A Mackensen, F Müller
Reduced cytotoxicity by mutation of lysine 590 of Pseudomonas exotoxin can be restored in an optimized, lysine-free immunotoxin. Immunotherapy advances 2 (1) (2022)
Gabriel Pasquarelli-do-Nascimento, Sabrina Azevedo Machado, Juliana Maria Andrade de Carvalho, Kelly Grace Magalhães
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. Immunotherapy advances 2 (1) (2022)
Simone Reinwald, Jennifer M Rolland, Robyn E O'Hehir, Menno C van Zelm
Peanut oral immunotherapy: current trends in clinical trials. Immunotherapy advances 2 (1) (2022)
Liam V Brown, Jonathan Wagg, Rachel Darley, Andy van Hateren, Tim Elliott, Eamonn A Gaffney, Mark C Coles
De-risking clinical trial failure through mechanistic simulation. Immunotherapy advances 2 (1) (2022)
Stephanie Schwartz, Nidhi Patel, Tyler Longmire, Pushpa Jayaraman, Xiaomo Jiang, Hongbo Lu, Lisa Baker, Janelle Velez, Radha Ramesh, Anne-Sophie Wavreille, Melanie Verneret, Hong Fan, Tiancen Hu, Fangmin Xu, John Taraszka, Marc Pelletier, Joy Miyashiro, Mikael Rinne, Glenn Dranoff, Catherine Sabatos-Peyton, Viviana Cremasco
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy advances 2 (1) (2022)
Rifat S Rahman, Duane R Wesemann
Immunology of allergen immunotherapy. Immunotherapy advances 2 (1) (2022)
Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro
Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. Immunotherapy advances 2 (1) (2022)
Abdulhadi H Jfri, Bonnie Leung, Jordan T Said, Yevgeniy R Semenov, Nicole R LeBoeuf
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors. Immunotherapy advances 2 (1) (2022)
Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer, Paul Garside
Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. Immunotherapy advances 2 (1) (2022)
Mike Bogetofte Barnkob, Kristoffer Vitting-Seerup, Lars Rønn Olsen
Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy. Immunotherapy advances 2 (1) (2022)
Tosca Holtrop, Kevin Budding, Arianne M Brandsma, Jeanette H W Leusen
Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer. Immunotherapy advances 2 (1) (2022)
Josephine Zhang, Jesús A Siller-Farfán
Current and future perspectives of chimeric antigen receptors against glioblastoma. Immunotherapy advances 2 (1) (2022)
Danijela Tatovic, M A McAteer, J Barry, A Barrientos, K Rodríguez Terradillos, I Perera, E Kochba, Y Levin, M Dul, S A Coulman, J C Birchall, C von Ruhland, A Howell, R Stenson, M Alhadj Ali, S D Luzio, G Dunseath, W Y Cheung, G Holland, K May, J R Ingram, M M U Chowdhury, F S Wong, R Casas, C Dayan, J Ludvigsson
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunotherapy advances 2 (1) (2022)
Beatriz Marton Freire, Filipe Menegatti de Melo, Alexandre S Basso
Adrenergic signaling regulation of macrophage function: do we understand it yet? Immunotherapy advances 2 (1) (2022)